A total of 59 patients received UCPVax; 95% had three prior lines of systemic therapy. No dose-limiting toxicity was observed in 15 patients treated in phase Ib. The maximum tolerated dose was 1 mg.
(RTTNews) - Drug major Merck & Co. Inc. (MRK) announced Friday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy KEYTRUDA as a single agent, for adjuvant treatment ...
Some people have such a hectic existence they give the impression that, in order to fit it all in, they must be paying someone else to do their sleeping for them. One such is Siddhartha Mukherjee. His ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback